Even with some recent wobbles in the start-up world, big sums are continuing to roll into technology start-ups.
Just a few days into 2016, Flatiron Health, a start-up that gathers and analyzes data on cancer treatments and sells software based on those insights, said it had raised $175 million in a funding round led by the pharmaceutical giant Roche. Flatiron declined to disclose its valuation.
As part of the deal, Flatiron gets more than money. Roche will buy several of Flatiron’s software products, which are based on subscriptions, in a move that is set to expand the start-up’s stream of recurring revenue and better position it for a future initial public offering. The partnership between the two companies is nonexclusive, and Flatiron can continue to work with other pharmaceutical companies.
